Duration of influenza vaccine effectiveness: A systematic review, meta-analysis, and meta-regression of test- negative design case-control studies

Journal of Infectious Diseases

Volumn 217, Issue 5, 2018, Pages 731-741

  Young, Barnaby ^a,b   Sadarangani, Sapna ^a,b   Jiang, Lili ^c   Wilder Smith, Annelies ^a,b,d   Chen, Mark I Cheng ^a,c  

^a TAN TOCK SENG HOSPITAL   (Singapore)

^b NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Decline; Influenza; Persistence; Test negative design; Tropics; Vaccination; Vaccine effectiveness

Indexed keywords

INFLUENZA VACCINE;

ARTICLE; DRUG EFFICACY; HERD IMMUNITY; HUMAN; INFLUENZA; INFLUENZA A; INFLUENZA A VIRUS; INFLUENZA B; INFLUENZA B VIRUS; INFLUENZA VACCINATION; META ANALYSIS; PRIORITY JOURNAL; SYSTEMATIC REVIEW; VIRUS STRAIN; ADOLESCENT; ADULT; AGED; CHILD; FEMALE; IMMUNOLOGY; INFANT; INFLUENZA A VIRUS (H1N1); INFLUENZA A VIRUS (H3N2); MALE; MIDDLE AGED; NEWBORN; PRESCHOOL CHILD; TIME FACTOR; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA B VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85044519501     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jix632     Document Type: Article

References (44)

1. Lee J, Boutz DR, Chromikova V, et al. Molecular-level analysis of the serum antibody repertoire in young adults before and after seasonal influenza vaccination. Nat Med 2016; 22:1456-64.
2. Coudeville L, Bailleux F, Riche B, Megas F, Andre P, Ecochard R. Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects model. BMC Med Res Methodol 2010; 10:18.
3. Song JY, Cheong HJ, Hwang IS, et al. Long-term immunogenicity of influenza vaccine among the elderly: Risk factors for poor immune response and persistence. Vaccine 2010; 28:3929-35.
4. Young B, Zhao X, Cook AR, Parry CM, Wilder-Smith A, I-Cheng MC. Do antibody responses to the influenza vaccine persist year-round in the elderly? A systematic review and meta-analysis. Vaccine 2017; 35:212-21.
5. Hirve S, Newman LP, Paget J, et al. Influenza seasonality in the tropics and subtropics-when to vaccinate? PLOS One 2016; 11:e0153003.
6. Ortiz JR, Perut M, Dumolard L, et al. A global review of national influenza immunization policies: Analysis of the 2014 WHO/UNICEF Joint Reporting Form on immunization. Vaccine 2016; 34:5400-5.
7. Goeijenbier M, van Genderen P, Ward BJ, Wilder-Smith A, Steffen R, Osterhaus ADME. Travellers and influenza: risks and prevention. J Travel Med 2017; 24.
8. Kissling E, Nunes B, Robertson C, et al. I-MOVE multicentre case-control study 2010/11 to 2014/15: Is there within-season waning of influenza type/subtype vaccine effectiveness with increasing time since vaccination? Euro Surveill 2016; 21.
9. Ferdinands JM, Fry AM, Reynolds S, et al. Intraseason waning of influenza vaccine protection: Evidence from the US Influenza Vaccine Effectiveness Network, 2011-12 through 2014-15. Clin Infect Dis 2017; 64:544-50.
10. De Serres G, Skowronski DM, Wu XW, Ambrose CS. The test-negative design: validity, accuracy and precision of vaccine efficacy estimates compared to the gold standard of randomised placebo-controlled clinical trials. Euro Surveill 2013; 18.
11. Year-round influenza vaccine effectiveness: a systematic review and meta-analysis of test-negative case-control studies. https://www.crd.york.ac.uk/PROSPERO/display-record.asp?ID=CRD42017071890. Accessed 15 August 2017.
12. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 2009; 6:e1000100.
13. Guyatt GH, Oxman AD, Vist GE, et al.; GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008; 336:924-6.
14. Ramsay LC, Buchan SA, Stirling RG, et al. The impact of repeated vaccination on influenza vaccine effectiveness: a systematic review and meta-analysis. BMC Med 2017; 15:159.
15. Review Manager (RevMan) [Computer program]. Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
16. R Development Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2008. ISBN 3-900051-07-0, http:// www.R-project.org.
17. Viechtbauer W. Conducting meta-analyses in R with the metafor package. J Stat Softw 2010; 36:1-48.
18. Levy JW, Simasathien S, Watanaveeradej V, et al. Influenza vaccine effectiveness in the tropics: moderate protection in a case test-negative analysis of a hospital-based surveillance population in Bangkok between August 2009 and January 2013. PloS One 2015; 10:e0134318.
19. Katz MA, Lebo E, Emukule GO, et al. Uptake and effectiveness of a trivalent inactivated influenza vaccine in children in urban and rural Kenya, 2010 to 2012. Pediatr Infect Dis J. 2016; 35:322-9.
20. Radin JM, Hawksworth AW, Myers CA, Ricketts MN, Hansen EA, Brice GT. Influenza vaccine effectiveness: Maintained protection throughout the duration of influenza seasons 2010-2011 through 2013-2014. Vaccine 2016; 34:3907-12.
21. Jimenez-Jorge S, de Mateo S, Delgado-Sanz C, et al. Effectiveness of influenza vaccine against laboratory-confirmed influenza, in the late 2011-2012 season in Spain, among population targeted for vaccination. BMC Infect Dis 2013; 13:441.
22. Castilla J, Martinez-Baz I, Martinez-Artola V, et al. Decline in influenza vaccine effectiveness with time after vaccination, Navarre, Spain, season 2011/12. Euro Surveill 2013; 18.
23. Pebody RG, Andrews N, McMenamin J, et al. Vaccine effectiveness of 2011/12 trivalent seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: evidence of waning intra-seasonal protection. Euro Surveill 2013; 18.
24. Kissling E, Valenciano M, Larrauri A, et al. Low and decreasing vaccine effectiveness against influenza A(H3) in 2011/12 among vaccination target groups in Europe: results from the I-MOVE multicentre case-control study. Euro Surveill 2013; 18.
25. Sullivan SG, Komadina N, Grant K, Jelley L, Papadakis G, Kelly H. Influenza vaccine effectiveness during the 2012 influenza season in Victoria, Australia: influences of waning immunity and vaccine match. J Med Virol 2014; 86:1017-25.
26. Andrews N, McMenamin J, Durnall H, et al. Effectiveness of trivalent seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2012/13 end of season results. Euro Surveill 2014; 19:5-13.
27. Pebody R, Warburton F, Andrews N, et al. Effectiveness of seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2014/15 end of season results. Euro Surveill 2015; 20.
28. Gherasim A, Pozo F, de Mateo S, et al.; cycEVA team and the VEVA Working Group. Waning protection of influenza vaccine against mild laboratory confirmed influenza A(H3N2) and B in Spain, season 2014-15. Vaccine 2016; 34:2371-7.
29. Pebody R, Warburton F, Ellis J, et al. Effectiveness of seasonal influenza vaccine for adults and children in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2015/16 end-of-season results. Euro Surveill 2016; 21.
30. Petrie JG, Ohmit SE, Truscon R, et al. Modest waning of influenza vaccine efficacy and antibody titers during the 2007-2008 influenza season. J Infect Dis 2016; 214:1142-1149.
31. Belongia EA, Sundaram ME, McClure DL, Meece JK, Ferdinands J, VanWormer JJ. Waning vaccine protection against influenza A (H3N2) illness in children and older adults during a single season. Vaccine 2015; 33:246-51.
32. Darvishian M, Bijlsma MJ, Hak E, van den Heuvel ER. Effectiveness of seasonal influenza vaccine in community-dwelling elderly people: a meta-analysis of test-negative design case-control studies. Lancet Infect Dis 2014; 14:1228-39.
33. Deiss RG, Arnold JC, Chen WJ, et al. Vaccine-associated reduction in symptom severity among patients with influenza A/H3N2 disease. Vaccine 2015; 33:7160-7.
34. DiazGranados CA, Dunning AJ, Kimmel M, et al. Efficacy of high-dose versus standard-dose influenza vaccine in older adults. N Engl J Med 2014; 371:635-45.
35. Dunkle LM, Izikson R, Patriarca P, et al.; PSC12 Study Team. Efficacy of recombinant influenza vaccine in adults 50 years of age or older. N Engl J Med 2017; 376:2427-36.
36. Wilkinson K, Wei Y, Szwajcer A, et al. Efficacy and safety of high-dose influenza vaccine in elderly adults: A systematic review and meta-analysis. Vaccine 2017; 35:2775-80.
37. Cox MM, Izikson R, Post P, Dunkle L. Safety, efficacy, and immunogenicity of Flublok in the prevention of seasonal influenza in adults. Ther Adv Vaccines 2015; 3:97-108.
38. Tsai TF. Fluad®-MF59®-Adjuvanted Influenza Vaccine in Older Adults. Infect Chemother 2013; 45:159-74.
39. Grohskopf LA, Sokolow LZ, Broder KR, et al. Prevention and control of seasonal influenza with vaccines. MMWR Recomm Rep 2016; 65:1-54.
40. Cordero E, Roca-Oporto C, Bulnes-Ramos A, et al.; TRANSGRIPE 1-2 Study Group. Two doses of inactivated influenza vaccine improve immune response in solid organ transplant recipients: results of TRANSGRIPE 1-2, a randomized controlled clinical trial. Clin Infect Dis 2017; 64:829-38.
41. Young B, Sadarangani S, Yew HS, et al. The immune response to 6-monthly versus annual standard dose inactivated trivalent influenza vaccination in older people: study protocol for a randomised clinical trial. Trials 2017; 18:67.
42. Bedford T, Riley S, Barr IG, et al. Global circulation patterns of seasonal influenza viruses vary with antigenic drift. Nature 2015; 523:217-20.
43. Foppa IM, Haber M, Ferdinands JM, Shay DK. The case test-negative design for studies of the effectiveness of influenza vaccine. Vaccine 2013; 31:3104-9.
44. Cowling BJ, Fang VJ, Nishiura H, et al. Increased risk of noninfluenza respiratory virus infections associated with receipt of inactivated influenza vaccine. Clin Infect Dis 2012; 54:1778-83.